Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tabelecleucel - Atara Biotherapeutics

Next Previous
Drug Profile

Tabelecleucel - Atara Biotherapeutics

Alternative Names: Allogeneic Epstein Barrr virus specific cytotoxic T-lymphocytes - Atara/MSKCC; ATA-129; EBV targeted T-cell therapy - Atara/MSKCC; EBV-CTL - Atara/MSKCC; EBV-specific T-cells - Atara/MSKCC; Ebvallo; EbvalloTM; Epstein-Barr virus specific cytotoxic T-lymphocytes - Atara/MSKCC; Epstein-Barr virus-specific T-cell therapy - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center; tab-cel

Latest Information Update: 14 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Atara Biotherapeutics
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lymphoproliferative disorders
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Lymphoproliferative disorders
  • Phase I/II Nasopharyngeal cancer

Most Recent Events

  • 07 May 2026 Pierre Fabre Pharmaceuticals aligns with the US FDA on a potential path forward for resubmission of the BLA of tabelecleucel for Lymphoproliferative disorders
  • 12 Mar 2026 The US FDA agrees to Type A meeting for the biologic license application for tabelecleucel
  • 02 Mar 2026 Pierre Fabre Pharmaceuticals submits request to US FDA for a Type A meeting on the biologic license application for tabelecleucel in relapsed/refractory Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top